Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

23.30USD
16 Feb 2018
Change (% chg)

$-0.24 (-1.02%)
Prev Close
$23.54
Open
$23.44
Day's High
$23.72
Day's Low
$22.94
Volume
65,259
Avg. Vol
97,758
52-wk High
$24.25
52-wk Low
$14.36

Chart for

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology... (more)

Overall

Beta: 2.67
Market Cap(Mil.): $857.97
Shares Outstanding(Mil.): 36.82
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Macrogenics Enters Research Collaboration With Roche

* MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE

Jan 04 2018

BRIEF-Macrogenics- increased number of directors that constitute board from eight to nine ​

* Macrogenics- increased number of directors that constitute board from eight to nine after approving appointment of Jay Siegel on Nov 13 - SEC filing ​ Source text: (http://bit.ly/2A2CHjE) Further company coverage:

Nov 16 2017

BRIEF-Macrogenics names Jay Siegel to its board of directors

* Macrogenics names Jay Siegel to its board of directors Source text for Eikon: Further company coverage:

Nov 15 2017

BRIEF-Macrogenics Posts Q3 loss of $1.28 per share

* Macrogenics provides update on corporate progress and third quarter 2017 financial results

Nov 08 2017

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

Oct 25 2017

BRIEF-Macrogenics advances two clinical DART molecules

* Macrogenics advances two first-in-class clinical DART molecules

Sep 05 2017

BRIEF-Macrogenics announces termination of duvortuxizumab collaboration

* Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen

Aug 31 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF225.50 +2.10
Roche Holding Ltd. (RO.S) CHF230.20 +2.60
Amgen, Inc. (AMGN.OQ) $183.55 -0.05
Xencor Inc (XNCR.OQ) $25.40 +0.75

Earnings vs. Estimates